daratumumab/hyaluronidase (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Multiple Myeloma

Pending FDA approval as new SC administration product for treatment of multiple myeloma

Next:

Pharmacology

Mechanism of Action

Monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells

Binding to CD38 is believed to induce rapid tumor cell death through programmed cell death, or apoptosis, and multiple immune-mediated mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity

Hyaluronidase human increases permeability of SC tissue by temporarily depolymerizing hyaluronan

Previous
Next:

Images

Previous
Next:
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.